EntryPoint Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
EntryPoint Capital's VRTX Position: Q2 2026 in Review
EntryPoint Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 523 shares — an estimated $234K sold.
EntryPoint Capital first reported a position in VRTX in Q4 2023 and held it in 3 quarters. The position peaked at $483K in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- EntryPoint Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- EntryPoint Capital sold 523 Vertex Pharmaceuticals shares in Q2 2026, an estimated $234K.
- EntryPoint Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 3 quarters.
- EntryPoint Capital's Vertex Pharmaceuticals position peaked at $483K in Q4 2025.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.